ARAY reminds me more of ISRG (which I owned) and HNSN (which I wanted to buy at $12, but I was waiting for a pullback...it's at $28 now).
I think in many ways these companies are easier for the general public and undereducated fund managers to understand, at least compared with pharmacotherapy.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.